JP2021070685A5 - - Google Patents

Download PDF

Info

Publication number
JP2021070685A5
JP2021070685A5 JP2020172258A JP2020172258A JP2021070685A5 JP 2021070685 A5 JP2021070685 A5 JP 2021070685A5 JP 2020172258 A JP2020172258 A JP 2020172258A JP 2020172258 A JP2020172258 A JP 2020172258A JP 2021070685 A5 JP2021070685 A5 JP 2021070685A5
Authority
JP
Japan
Prior art keywords
magnesium
component
mass
solid preparation
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020172258A
Other languages
Japanese (ja)
Other versions
JP2021070685A (en
Filing date
Publication date
Application filed filed Critical
Publication of JP2021070685A publication Critical patent/JP2021070685A/en
Publication of JP2021070685A5 publication Critical patent/JP2021070685A5/ja
Pending legal-status Critical Current

Links

Claims (10)

（Ａ）塩類下剤のマグネシウム塩、及びビサコジルからなる群から選ばれる少なくとも１種、及び（Ｂ）プランタゴ・オバタを含有し、
成分（Ａ）が酸化マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）酸化マグネシウム１質量部に対して１０～２０質量部であり、
成分（Ａ）が水酸化マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）水酸化マグネシウム１質量部に対して２～２０質量部であり、
成分（Ａ）が硫酸マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）硫酸マグネシウム１質量部に対して０．１～５質量部、
であることを特徴とする固形製剤。 (A) containing at least one member selected from the group consisting of magnesium salts of salt laxatives and bisacodyl, and (B) Plantago ovata;
When component (A) is magnesium oxide, the content of component (B) is 10 to 20 parts by mass per 1 part by mass of magnesium oxide (A),
When component (A) is magnesium hydroxide, the content of component (B) is 2 to 20 parts by mass per 1 part by mass of magnesium hydroxide (A),
When component (A) is magnesium sulfate, the content of component (B) is 0.1 to 5 parts by mass per 1 part by mass of (A) magnesium sulfate,
A solid preparation characterized by: （Ａ）塩類下剤のマグネシウム塩が酸化マグネシウム、水酸化マグネシウム、硫酸マグネシウム、及び炭酸マグネシウムからなる群より選ばれる少なくとも１種である請求項１に記載の固形製剤。 The solid preparation according to claim 1, wherein the magnesium salt of the salt laxative (A) is at least one selected from the group consisting of magnesium oxide, magnesium hydroxide, magnesium sulfate, and magnesium carbonate. 成分（Ａ）が炭酸マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）炭酸マグネシウム１質量部に対して０．１～１０質量部であることを特徴とする請求項１又は２に記載の固形製剤。 According to claim 1 or 2, when component (A) is magnesium carbonate, the content of component (B) is 0.1 to 10 parts by mass per 1 part by mass of magnesium carbonate (A). solid formulation. （Ｂ）プランタゴ・オバタの含有量が、固形製剤全体に対して１０～９５質量％である、請求項１～３のいずれかに記載の固形製剤。 (B) The solid preparation according to any one of claims 1 to 3, wherein the content of Plantago ovata is 10 to 95% by mass based on the entire solid preparation. （Ａ）酸化マグネシウムの含有量が、固形製剤全体に対して１～９質量％である、請求項１、２又は４のいずれかに記載の固形製剤。 The solid preparation according to claim 1, wherein the content of (A) magnesium oxide is 1 to 9% by mass based on the entire solid preparation. （Ａ）水酸化マグネシウムの含有量が、固形製剤全体に対して５～４０質量％である、請求項１、２又は４のいずれかに記載の固形製剤。 The solid preparation according to claim 1, wherein the content of (A) magnesium hydroxide is 5 to 40% by mass based on the entire solid preparation. さらに有機酸を含む請求項１～６のいずれかに記載の固形製剤。 The solid preparation according to any one of claims 1 to 6, further comprising an organic acid. 剤形が口腔内崩壊錠、チュアブル錠、素錠、顆粒剤、又は散剤である請求項１～７のいずれかに記載の固形製剤。 The solid preparation according to any one of claims 1 to 7, whose dosage form is an orally disintegrating tablet, a chewable tablet, a plain tablet, a granule, or a powder. （Ｂ）プランタゴ・オバタが、プランタゴ・オバタ種子、又はプランタゴ・オバタ種皮である、請求項１～８のいずれかに記載の固形製剤。 (B) The solid preparation according to any one of claims 1 to 8, wherein the Plantago ovata is a Plantago ovata seed or a Plantago ovata seed coat. （Ａ）塩類下剤のマグネシウム塩、及びビサコジルからなる群から選ばれる少なくとも１種、及び（Ｂ）プランタゴ・オバタを含有し、(A) containing at least one member selected from the group consisting of magnesium salts of salt laxatives and bisacodyl, and (B) Plantago ovata;
成分（Ａ）が酸化マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）酸化マグネシウム１質量部に対して１０～２０質量部であり、When component (A) is magnesium oxide, the content of component (B) is 10 to 20 parts by mass per 1 part by mass of magnesium oxide (A),
成分（Ａ）が水酸化マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）水酸化マグネシウム１質量部に対して２～２０質量部であり、When component (A) is magnesium hydroxide, the content of component (B) is 2 to 20 parts by mass per 1 part by mass of magnesium hydroxide (A),
成分（Ａ）が硫酸マグネシウムの場合、（Ｂ）成分の含有量は（Ａ）硫酸マグネシウム１質量部に対して０．１～５質量部、When component (A) is magnesium sulfate, the content of component (B) is 0.1 to 5 parts by mass per 1 part by mass of (A) magnesium sulfate,
である固形製剤の製造方法であって、A method for producing a solid preparation, comprising:
（Ａ）塩類下剤のマグネシウム塩、及びビサコジルからなる群から選ばれる少なくとも１種、及び（Ｂ）プランタゴ・オバタを混合する工程を有する、前記固形製剤の製造方法。The method for producing the solid preparation, comprising the step of mixing (A) at least one member selected from the group consisting of magnesium salts of salt laxatives and bisacodyl, and (B) Plantago ovata.
JP2020172258A 2019-10-28 2020-10-13 Solid preparation Pending JP2021070685A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019195376 2019-10-28
JP2019195376 2019-10-28

Publications (2)

Publication Number Publication Date
JP2021070685A JP2021070685A (en) 2021-05-06
JP2021070685A5 true JP2021070685A5 (en) 2023-10-13

Family

ID=75714017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020172258A Pending JP2021070685A (en) 2019-10-28 2020-10-13 Solid preparation

Country Status (1)

Country Link
JP (1) JP2021070685A (en)

Similar Documents

Publication Publication Date Title
SA112330689B1 (en) Capsule formulation comprising montelukast and levocetirizine
HRP20161262T1 (en) Ulipristal acetate tablets
JP2014237658A5 (en)
JP2008516004A5 (en)
SK6102001A3 (en) Pharmaceutical moxifloxacin preparation
SI2760821T1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
JP2023165999A5 (en)
US4198435A (en) Pharmaceutical compositions
JP2021070685A5 (en)
JP2009514786A5 (en)
JP2008503574A5 (en)
RU2004118714A (en) METHOD FOR MANUFACTURE OF TABLETS CONTAINING S-ADENOSYLMETHIONINE
SE509694C2 (en) Pharmaceutical compositions containing ranitidine / bismuth carboxylic acid salts
WO2001019350A1 (en) Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US4064230A (en) Polyenic macrolide compositions
RU2010153977A (en) COMPOSITIONS CONTAINING EUPHORBIA PROSTRATA AND METHOD FOR PRODUCING THEM
JP2010509293A5 (en)
WO1999062559A1 (en) Pharmaceutical tablets comprising cefuroxime axetil
US3787581A (en) Pharmaceutical compositions and methods of treatment
CN103520130A (en) Montelukast sodium time-selection controlled-release tablet and preparation method thereof
CN101849939A (en) Medicinal composition taking ipratropium bromide and salbutamol as main active ingredients
CN102048822A (en) Washing solution for preventing and treating sow endometritis
WO2004058228A1 (en) Enteric coated fluoxetine composition
CN108969575A (en) A kind of pharmaceutical composition and its preparation method and application for treating canker sore and exanthemv
JPS5938206B2 (en) Bronchial asthma treatment whose main ingredient is coenzyme Q